Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 | P07550 | 11/20 | 0.55 |
| ▸ | ADRB1 | P08588 | 5/20 | 0.55 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | HTR1A | P08908 | 1/20 | 0.45 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.45 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.45 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.45 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.45 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | PNMT | P11086 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9446813 | 0.87 | ADRB2 (0.55) | ADRB2ADRB1LMNAHTR1ASLC6A2 | |
| SCHEMBL11640810 | 0.86 | ADRB2 (0.53) | ADRB2ADRB1LMNAHTR1ASLC6A2 | |
| SCHEMBL31749061 | 0.86 | ADRB2 (0.53) | ADRB2ADRB1LMNAHTR1ASLC6A2 | |
| SCHEMBL6323504 | 0.82 | ADRB1 (0.56) | ADRB2ADRB1LMNAHTR1ASLC6A2 | |
| SCHEMBL3983553 | 0.82 | ADRB1 (0.56) | ADRB2ADRB1LMNAHTR1ASLC6A2 | |
| SCHEMBL11024777 | 0.80 | ADRB2 (0.54) | ADRB2ADRB1LMNAHTR1ASLC6A2 | |
| Mabuterol SCHEMBL82440 | 0.80 | ADRB2 (0.76) | ADRB2ADRB1LMNAHTR1ASLC6A2 | |
| Mabuterol SCHEMBL29384375 | 0.79 | LMNA (0.77) | ADRB2ADRB1LMNAHTR1ASLC6A2 | |
| Hydrochloric Acid SCHEMBL11642110 | 0.79 | ADRB2 (0.55) | ADRB2ADRB1LMNAHTR1ASLC6A2 | |
| Mabuterol SCHEMBL123796 | 0.79 | LMNA (0.77) | ADRB2ADRB1LMNAHTR1ASLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6933296-B2 | Compounds effective as β2-adrenoreceptor agonists as well as PDE4-inhibitors | ALTANA PHARMA B.V. (NL) | 2005-08-23 | — | — | US | disclosed |
| US-20030195215-A1 | Compounds effective as beta-2 adrenoreceptor agonists as well pde4-inhibitors | ALTANA PHARMA B.V. (NL) | 2003-10-16 | — | — | US | disclosed |
| EP-1296956-A1 | COMPOUNDS EFFECTIVE AS BETA-2-ADRENORECEPTOR AGONISTS AS WELL AS PDE4-INHIBITORS | ALTANA Pharma AG (DE) | 2003-04-02 | — | — | EP | disclosed |
| WO-2001094319-A1 | COMPOUNDS EFFECTIVE AS BETA-2-ADRENORECEPTOR AGONISTS AS WELL AS PDE4-INHIBITORS | ALTANA PHARMA AG (DE) | 2001-12-13 | — | — | WO | disclosed |
| US-5216170-A | Promoters of livestock; treatment of obesity | BAYER AKTIENGESELLSCHAFT (DE) | 1993-06-01 | — | — | US | disclosed |
| US-5028617-A | Heteroarylethanol-pyridylalkylamines for controlling animal growth | BAYER AKTIENGESELLSCHAFT (DE) | 1991-07-02 | — | — | US | disclosed |
| EP-0379928-A2 | Aryl- and heteroarylethanol-pyridylalkylamines, process for their preparation and their use as performance stimulators by animals and as anti-adipositas agent | BAYER AG (DE) | 1990-08-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030195215-A1 | Compounds effective as beta-2 adrenoreceptor agonists as well pde4-inhibitors | ADRB1, ADRB2, ADRA1D | ADRB2 2/4885ADRB1 1/4885LMNA 3762/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.